Medication, toxic, and vitamin-related neuropathies

CONTINUUM Lifelong Learning in Neurology

Volumn 18, Issue 1, 2012, Pages 139-160

  Morrison, Brett ^a   Chaudhry, Vinay ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; CHLORAMPHENICOL; CLOFAZIMINE; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; DOXORUBICIN; ETHAMBUTOL PLUS ISONIAZID; FIALURIDINE; FLUINDOSTATIN; HYDRALAZINE; ISONIAZID; LAMIVUDINE; METRONIDAZOLE; MEVINOLIN; NITROFURANTOIN; PEFLOXACIN; PERHEXILINE; PITAVASTATIN; PRAVASTATIN; PROCAINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; STAVUDINE; UNINDEXED DRUG; VINCRISTINE; ZALCITABINE;

ACHILLES REFLEX; ADULT; AGED; ALLERGIC REACTION; ANGINA PECTORIS; ATAXIA TELANGIECTASIA; BACTERIAL INFECTION; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CROHN DISEASE; CYSTIC FIBROSIS; DIABETES MELLITUS; ELECTRODIAGNOSIS; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEPROSY; MALE; MONONEUROPATHY MULTIPLEX; NEUROPATHIC PAIN; NEUROPATHY; NONHODGKIN LYMPHOMA; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PYRIDOXINE DEFICIENCY; RESPIRATORY TRACT INFECTION; REVIEW; SENSORY NEUROPATHY; SPINAL GANGLION; TOXOPLASMOSIS; TUBERCULOSIS; URINARY TRACT INFECTION;

EID: 84856841703     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000411565.49332.84     Document Type: Review

References (60)

1. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58(5):295-300.
2. Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001;6(1):14-20. (Pubitemid 32240452)
3. Brew BJ, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS 2003;17(7):1094-1096. (Pubitemid 36549727)
4. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 2010;24(8):655-667.
5. McCarty M. How clinically relevant is Dapsone-related peripheral neuropathy? An overview of available data with emphasis on clinical recognition. J Clin Aesthet Dermatol 2010;3(3):19-21.
6. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101(1):92-104. (Pubitemid 14088076)
7. Toole JF, Parrish ML. Nitrofurantoin polyneuropathy. Neurology 1973;23(5): 554-559.
8. Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001;35(12):1540-1547. (Pubitemid 34027449)
9. Aoun M, Jacquy C, Debusscher L, et al. Peripheral neuropathy associated with fluoroquinolones. Lancet 1992; 340(8811):127.
10. Kapoor K, Chandra M, Nag D, et al. Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res 1999;19(3):83-88. (Pubitemid 30162679)
11. Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66(7):865-869.
12. Ahmad S. Procainamide and peripheral neuropathy. South Med J 1981;74(4): 509-510. (Pubitemid 12216228)
13. Raskin NH, Fishman RA. Pyridoxine-deficiency neuropathy due to hydralazine. N Engl J Med 1965;273(22):1182-1185.
14. Said G. Perhexiline neuropathy: a clinicopathological study. Ann Neurol 1978; 3(3):259-266. (Pubitemid 8364356)
15. Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58(9): 1333-1337. (Pubitemid 34507158)
16. Gaist D, Garća Rodŕguez LA, Huerta C, et al. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001;56(12):931-933. (Pubitemid 33788572)
17. Umapathi T, ChaudhryV. Toxic neuropathy. Curr Opin Neurol 2005;18(5):574-580. (Pubitemid 41476146)
18. Sioka C, KyritsisAP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009;63(5):761-767.
19. Brouwers EE, Huitema AD, Boogerd W, et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009; 48(6):832-841.
20. Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29(3):387-392. (Pubitemid 38269758)
21. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8(6):508-513. (Pubitemid 37467365)
22. ChaudhryV, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008; 13(4):275-282.
23. ChaudhryV, Eisenberger MA, Sinibaldi VJ, et al. A prospective study of suramin-induced peripheral neuropathy. Brain 1996;119(pt 6): 2039-2052. (Pubitemid 27032634)
24. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002;59(12):1872-1875. (Pubitemid 36076557)
25. Melgaard B, Hansen HS, Kamieniecka Z, et al. Misonidazole neuropathy: a clinical, electrophysiological, and histological study. Ann Neurol 1982;12(1):10-17. (Pubitemid 12080458)
26. Fam AG, Gordon DA, Sarkozi J, et al. Neurologic complications associated with gold therapy for rheumatoid arthritis. J Rheumatol 1984;11(5):700-706. (Pubitemid 15215063)
27. Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987;316(25):1562-1568. (Pubitemid 17083593)
28. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000;27(12): 2927-2931.
29. Wilson JR, Conwit RA, Eidelman BH, et al. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 1994;17(5):528-532. (Pubitemid 24143333)
30. Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004; 75(6):580-585. (Pubitemid 38746609)
31. Gherardi R, Louarn F, Benvenuti C, et al. Peripheral neuropathy in patientstreated with almitrine dimesylate. Lancet 1985; 1(8440):1247-1250. (Pubitemid 15036470)
32. Lovelace RE, Horwitz SJ. Peripheral neuropathy in long-term diphenylhydantoin therapy. Arch Neurol 1968;18(1):69-77.
33. BergerAR, Schaumburg HH, Schroeder C, et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992; 42(7):1367-1370.
34. Thomson RM, Parry GJ. Neuropathies associated with excessive exposure to lead. Muscle Nerve 2006;33(6):732-741. (Pubitemid 43862454)
35. Ratnaike RN. Acute and chronicarsenic toxicity. Postgrad Med J 2003;79(933):391-396.
36. Zhao G, Ding M, Zhang B, et al. Clinical manifestations and management of acute thallium poisoning. Eur Neurol 2008;60(6): 292-297.
37. Clifton JC 2nd. Mercury exposure and public health. Pediatr Clin North Am 2007;54(2): 237-269, viii.
38. Albrecht J, Matyja E. Glutamate: a potential mediator of inorganic mercury neurotoxicity. Metab Brain Dis 1996;11(2): 175-184. (Pubitemid 26177660)
39. Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry 2001;70(1):4-8. (Pubitemid 32096112)
40. Watkins SM, Reich A, Fleming LE, Hammond R. Neurotoxic shellfish poisoning. Mar Drugs 2008;6(3):431-455.
41. Kanchanapongkul J. Pufferfish poisoning: clinical features and management experience in 25 cases. J Med Assoc Thai 2001;84(3):385-389. (Pubitemid 33710206)
42. Jokanovic M, Stukalov PV, Kosanovic M. Organophosphate induced delayed polyneuropathy. Curr Drug Targets CNS Neurol Disord 2002;1(6):593-602.
43. Reddy NJ, Sudini M, Lewis LD. Delayed neurological sequelae from ethylene glycol, diethylene glycol and methanol poisonings. Clin Toxicol 2010;48(10):967-973.
44. Chang AP, England JD, Garcia CA, Sumner AJ. Focal conduction block in n-hexane polyneuropathy. Muscle Nerve 1998;21(7): 964-969. (Pubitemid 28262300)
45. Souyri F, Chretien M, Droz B. 'Acrylamide-induced' neuropathy and impairment of axonal transport of proteins. I. Multifocal retention of fasttransported proteins at the periphery of axons as revealed by light microscope radioautography. Brain Res 1981;205(1): 1-13. (Pubitemid 11205748)
46. LeWitt PA. The neurotoxicity of the rat poison vacor. A clinical study of 12 cases. N Engl J Med 1980;302(2):73-77.
47. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977;40(11):1072-1082. (Pubitemid 8261758)
48. Koike H, Iijima M, Sugiura M, et al. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol 2003;54(1):19-29. (Pubitemid 36764978)
49. Palliyath SK, Schwartz BD, Gant L. Peripheral nerve functions in chronic alcoholic patients on disulfiram: a six month follow up. J Neurol Neurosurg Psychiatry 1990;53(3): 227-230. (Pubitemid 20101746)
50. Kinsella LJ, Green R. 'Anesthesia paresthetica': nitrous oxide-induced cobalamin deficiency. Neurology 1995;45(8):1608-1610.
51. Calderon-Gonzalez R, Rizzi-Hernandez H. Buckthorn polyneuropathy. N Engl J Med 1967;277(2):69-71.
52. Vedanarayanan VV, Evans OB, Subramony SH. Tick paralysis in children: electrophysiology and possibility of misdiagnosis. Neurology 2002;59(7): 1088-1090.
53. 12 deficiency presenting as a peripheral neuropathy. South Med J 2010;103(3): 265-267.
54. 12 deficiency: a clinical and electrophysiological profile. Electromyogr Clin Neurophysiol 2005;45(5):273-284. (Pubitemid 41358612)
55. Singleton CK, Martin PR. Molecular mechanisms of thiamine utilization. Curr Mol Med 2001;1(2):197-207. (Pubitemid 33772043)
56. 6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis 2006;29(2-3):317-326. (Pubitemid 43880627)
57. Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol 2004;43(1):1-5. (Pubitemid 38180577)
58. MullerDP, Goss-Sampson MA. Neurochemical, neurophysiological, and neuropathological studies in vitamin E deficiency. Crit Rev Neurobiol 1990;5(3):239-263.
59. Kaler SG. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol 2011;7(1):15-29.
60. Goodman BP, Bosch EP, RossMA, et al. Clinical and electrodiagnostic findings in copper deficiency myeloneuropathy. J Neurol Neurosurg Psychiatry 2009;80(5):524-527.